<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02245269</url>
  </required_header>
  <id_info>
    <org_study_id>1182.21</org_study_id>
    <nct_id>NCT02245269</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of Atorvastatin With Tipranavir/Ritonavir and the Effect of Antacid on the Pharmacokinetics of Single-Dose Tipranavir/Ritonavir in Healthy Volunteers</brief_title>
  <official_title>A Two-way Pharmacokinetic Interaction Study of Single-Dose Atorvastatin (LIPITOR®) With Tipranavir/Ritonavir (500mg/200mg) at Steady-State and the Effect of Antacid (MAALOX®) on the Pharmacokinetics of Single-Dose Tipranavir/Ritonavir (500mg/200mg) in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      Study to determine the effects of combined tipranavir and ritonavir treatment (at
      steady-state) on the single-dose pharmacokinetics of atorvastatin, the effects of single-dose
      atorvastatin on the steady-state pharmacokinetics of tipranavir, and the effects of antacid
      on the pharmacokinetics of tipranavir
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2003</start_date>
  <primary_completion_date type="Actual">October 2003</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the plasma drug concentration-time curve from time zero to infinity of the analyte (AUC0-∞)</measure>
    <time_frame>up to day 22</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum plasma concentration of the analyte (Cmax)</measure>
    <time_frame>up to day 22</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Drug concentration of the analyte in plasma at 12 hours after administration (Cp12h)</measure>
    <time_frame>up to day 22</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-12 hours of the analyte</measure>
    <time_frame>up to day 22</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Oral clearance (CL/F)</measure>
    <time_frame>up to day 22</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution (V)</measure>
    <time_frame>up to day 22</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of maximum concentration (tmax)</measure>
    <time_frame>up to day 22</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent terminal half life (t1/2)</measure>
    <time_frame>up to day 22</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Residence Time (MRT)</measure>
    <time_frame>up to day 22</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hepatic cytochrome P450 3A4 activity using the Erythromycin Breath Test</measure>
    <time_frame>Days 7-10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse events</measure>
    <time_frame>up to day 22</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with clinically relevant changes in laboratory tests</measure>
    <time_frame>up to day 22</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>TPV/r + Atorvastatin followed by TPV/r + antacid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Day 1: first dose of ATV Day 8: single dose of TPV/r Day 13: single dose of TPV/r, followed by a single dose of Maalox Days 14-21: morning and evening doses of TPV/r on Day 20: second dose of ATV</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tipranavir</intervention_name>
    <arm_group_label>TPV/r + Atorvastatin followed by TPV/r + antacid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ritonavir</intervention_name>
    <arm_group_label>TPV/r + Atorvastatin followed by TPV/r + antacid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin</intervention_name>
    <arm_group_label>TPV/r + Atorvastatin followed by TPV/r + antacid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Maalox</intervention_name>
    <description>Aluminum Hydroxide; Magnesium Hydroxide; Simethicone</description>
    <arm_group_label>TPV/r + Atorvastatin followed by TPV/r + antacid</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male and female subjects between 18 and 60 years of age inclusive

          2. A Body Mass Index (BMI) between 18 and 29 kg/m2

          3. Signed informed consent prior to trial participation

          4. Ability to swallow numerous study medications

          5. Acceptable laboratory values that indicate adequate baseline organ function are
             required at the time of screening. Laboratory values are considered to be acceptable
             if severity is less than or equal to Grade 1, based on the AIDS Clinical Trials Group
             Grading Scale

          6. Acceptable medical history, physical examination and ECG, and chest X-ray (if not
             conducted within the last 12 months) are required prior to entering the treatment
             phase of the study

          7. Willingness to abstain from alcohol starting 2 days prior to any administration study
             drug up to the end of the study. Red wine must not be ingested within 5 days prior to
             treatment and throughout the study

          8. Willingness to abstain from the following starting 10 days prior to any administration
             of study drug up until the end of the study:

             • Grapefruit or grapefruit juice or products containing grapefruit juice

          9. Willingness to abstain from ingesting Seville oranges, garlic supplements, St. John's
             Wort, or Milk Thistle, within 5 days of treatment and for the duration of the study

         10. Willingness to abstain from methylxanthine-containing drinks or foods (coffee, tea,
             cola, energy drinks, chocolate, etc.) within 72 hours of each pharmacokinetic (PK)
             sampling day and until after the last sample from each of the intensive sampling days
             is collected

         11. Willingness to abstain from over the counter herbal medications for the duration of
             the study

         12. Willingness to abstain from vigorous physical exercise during PK Days

         13. Reasonable probability for completion of the study

        Exclusion Criteria:

          1. Female subjects who are of reproductive potential who:

               -  Have positive serum β-human chorionic gonadotropin at Visit 1, or on Day 0

               -  Have not been using a barrier contraceptive method for at least 3 months prior to
                  Day 0 (Visit 2)

               -  Are not willing to use a reliable method of barrier contraception (such as
                  diaphragm or condoms), during the trial and 30 days after completion/termination

               -  Are breast-feeding

          2. Use of any pharmacological contraceptive (including oral, patch or injectable
             contraceptives) for 1 month prior to study initiation and for the duration of the
             study

          3. Use of hormone replacement therapy for 1 month prior to study initiation and for the
             duration of the study

          4. Participation in another trial with an investigational medicine within 60 days prior
             to Day 0 (Visit 2)

          5. Use of any medication listed in the protocol within 30 days prior to Day 0 (Visit 2)

          6. Administration of antibiotics within 10 days prior to Day 0 (Visit 2) or during the
             trial

          7. History of acute illness within the past sixty (60) days. Subjects will be excluded
             for these disorders greater than sixty days if, in the opinion of the investigator,
             the subject does not qualify as a healthy volunteer

          8. Have serological evidence of Hepatitis B or C Virus

          9. Have serological evidence of exposure to HIV

         10. Recent history of alcohol or substance abuse (within 6 months of study period)

         11. Smokers who smoke greater than 10 cigarettes or 3 cigars or 3 pipes per day; inability
             to refrain from smoking during the trial

         12. Blood or plasma donations within 30 days prior to Day 0 (Visit 2) or during the trial

         13. Subjects with a seated systolic blood pressure either &lt;100 mm Hg or &gt;150 mm Hg;
             resting heart rate either &lt;50 beats/min or &gt;90 beats/min

         14. Subjects with a history of any illness or allergy that, in the opinion of the
             investigator,might confound the results of the study or pose additional risk in
             administering Tipranavir,Ritonavir, atorvastatin or erythromycin to the subject

         15. Subjects who are currently taking any over-the-counter drug within 7 days prior to Day
             0,(Visit 2) or who are currently taking any prescription drug that, in the opinion of
             the investigator in consultation with the clinical monitor, might interfere with
             either the absorption, distribution or metabolism of the test substances

         16. Known hypersensitivity to Tipranavir,Ritonavir, sulfonamides, atorvastatin,
             erythromycin or saccharin

         17. Inability to comply with the protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>22 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://trials.boehringer-ingelheim.com</url>
  </link>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 18, 2014</study_first_submitted>
  <study_first_submitted_qc>September 18, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2014</study_first_posted>
  <last_update_submitted>September 18, 2014</last_update_submitted>
  <last_update_submitted_qc>September 18, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 19, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Tipranavir</mesh_term>
    <mesh_term>Antacids</mesh_term>
    <mesh_term>Aluminum hydroxide, magnesium hydroxide, drug combination</mesh_term>
    <mesh_term>Anti-Ulcer Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

